Tags : Junshi Biosciences

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study

Shots:   The P-III Jupiter-02 Study involve assessing of Toripalimab vs PBO in combination with + Gemcitabine/ Cisplatin for 1L treatment of 289 patients with recurrent or metastatic NPC The study resulted in meeting its pre-specified 1EPs of PFS and has expanded the PFS. The company will submit the BLA to NMPA & other countries Toripalimab […]Read More